lilly glp-1 drugs launches pill, kicking off showdown with Novo Nordisk Lilly orforglipron oral GLP-1 phase

Background Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) reduce the risk of major adverse cardiovascular events (MACE) in patients with type 2 diabetes mellitus (T2DM)

The convergence of chronic inflammation, mitochondrial dysfunction and altered protein metabolism makes individuals with metabolic diseases particularly vulnerable to sarcopenia

Larger randomized controlled trials with long-term follow-up are necessary to confirm these associations and evaluate the risk-benefit ratios

The inclusion of Akkermansia muciniphilaa microbe studied for its role in gut barrier health and metabolic signalingmakes this formula unique among microbiome supplements

Limited evidence suggests that combined SGLT2is/GLP1-RAs therapy can potentially improve most but not all outcomes

Worried about losing too much muscle on Ozempic, Wegovy, or Mounjaro